Important sources of variability in clinical studies of neutralizing antibodies against interferon beta

Journal of the Neurological Sciences

Volumn 272, Issue 1-2, 2008, Pages 8-19

  Hurwitz, B J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical outcomes; Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INCIDENCE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SENSITIVITY ANALYSIS;

ANTIBODIES; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 48349102333     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.05.004     Document Type: Review

References (48)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. Paty D.W., and Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43 (1993) 662-667
3. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
4. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
5. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
6. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
7. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 9139 (1998) 1498-1504
8. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
9. Goodin D.S., Frohman E.M., Hurwitz B., O'Connor P.W., Oger J.J., Reder A.T., et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68 (2007) 977-984
10. Deisenhammer F., Schellekens H., and Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 251 Suppl 2 (2004) II31-II39
11. Files J.G., Gray J.L., and Do L.T. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 18 (1998) 1019-1024
12. Files J.G., Hargrove D., Delute L., and Cantillon M. Measured neutralizing titers of IFNb neutralizing antibodies (NAbs) can depend on the preparations of IFNb used in the assay. J Interferon Cytokine Res 27 (2007) 637-642
13. Petkau A.J., White R.A., Ebers G.C., Reder A.T., Sibley W.A., Lublin F.D., et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 10 (2004) 126-138
14. Sorensen P.S., Ross C., and Clemmesen K.M. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
15. Hemmer B., Stuve O., Kieseier B., Schellekens H., and Hartung H.P. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 4 (2005) 403-412
16. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20 Suppl 6 (2005) vi3-vi9
17. Schellekens H., and Casadevall N. Immunogenicity of biopharmaceuticals. The European perspective. Dev Biol (Basel) 112 (2003) 23-28
18. Schellekens H., and Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251 Suppl 2 (2004) II4-II9
19. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., and Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
20. Collins P.W. Novel therapies for immune tolerance in haemophilia A. Haemophilia 12 Suppl 6 (2006) 94-100
21. Zhao H., Bailey L.A., and Grabowski G.A. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 30 (2003) 90-96
22. Walford S., Allison S.P., and Reeves W.G. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22 (1982) 106-110
23. Kagawa Y., Takasaki S., Utsumi J., Hosoi K., Shimizu H., Kochibe N., et al. Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J Biol Chem 263 (1988) 17508-17515
24. McCullagh K.G., Davies J.A., Sim I.S., Dawson K.M., O'Neill G.J., Doel S.M., et al. Biological properties of human interferon beta 1 synthesized in recombinant bacteria. J Interferon Res 3 (1983) 97-111
25. Gneiss C., Reindl M., Berger T., Lutterotti A., Ehling R., Egg R., et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 24 (2004) 283-290
26. Bertolotto A., Deisenhammer F., Gallo P., and Solberg S.P. Immunogenicity of interferon beta: differences among products. J Neurol 251 Suppl 2 (2004) II15-II24
27. Sorensen P.S., Koch-Henriksen N., and Bendtzen K. Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis?. Mult Scler 13 (2007) 616-621
28. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73 (2002) 148-153
29. Ross C., Clemmesen K.M., Svenson M., Sørensen P.S., Koch-Henriksen N., Skovgaard G.L., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48 (2000) 706-712
30. Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 9316 (2002) 1453-1460
31. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., et al. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031-2037
32. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59 (2002) 1496-1506
33. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 (1998) 1266-1272
34. Sominanda A., Rot U., Suoniemi M., Deisenhammer F., Hillert J., and Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13 (2007) 208-214
35. Freedman M.S., Francis G.S., Sanders E.A., Rice G.P., O'Connor P., Comi G., et al. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11 (2005) 41-45
36. Vartanian T., Solberg S.P., and Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol 251 Suppl 2 (2004) II25-II30
37. Rice G.P., Paszner B., Oger J., Lesaux J., Paty D., and Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52 (1999) 1277-1279
38. Gneiss C., Reindl M., Lutterotti A., Ehling R., Egg R., Khalil M., et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10 (2004) 507-510
39. Petersen B., Bendtzen K., Koch-Henriksen N., Ravnborg M., Ross C., and Sorensen P.S. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 12 (2006) 247-252
40. Francis G.S., Rice G.P., and Alsop J.C. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48-55
41. Panitch H., Goodin D., Francis G., Chang P., Coyle P., O'Connor P., et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 239 (2005) 67-74
42. Prlic M., and Bevan M.J. An antibody paradox, resolved. Science 311 (2006) 1875-1876
43. Noronha A.B., Antel J.P., Roos R.P., and Medof R.P. Circulating immune complexes in neurologic disease. Neurology 31 (1981) 1402-1407
44. Goodin D.S., Hurwitz B., and Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35 (2007) 173-187
45. Freedman M.S., Edan G., Hartung H.P., Kappos L., Miller D.H., Montalban X., et al. The Betaferon® in Newly Emerging multiple sclerosis For initial Treatment (BENEFIT) studies: neutralising antibodies did not affect clinical outcomes after 3 years. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (2007) P185
46. Boz C., Oger J., Gibbs E., and Grossberg S.E. Neurologist of the UBC MS Clinic. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 13 (2007) 1127-1137
47. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56 (2001) 1628-1636
48. Deisenhammer F. Neutraliizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-ß therapy. Mult Scler 13 (2007) S44-S48